By Fineline Cube 
On July 22, 2025, the innovative non-pharmacological ADHD treatment medical device “Smile” (ADHD Transcutaneous Nerve Electrical Stimulator) was officially launched in the Lecheng Pilot Zone. This marks a significant advancement in the treatment landscape for ADHD, offering a new option for children aged 7 to 12 years.
Smile System Overview
The Smile System, developed and produced by Korean Nu Eyne, received marketing approval from the US FDA in 2023. It is indicated as a monotherapy for children with ADHD who are not currently taking prescription ADHD medications.
Technology and Mechanism
Unlike traditional pharmacological treatments, which can have variable efficacy and significant side effects, the Smile System utilizes external trigeminal nerve stimulation (eTNS) technology. The device delivers gentle electrical stimulation to the trigeminal nerve via a forehead patch while the child is sleeping. This activation precisely targets brain regions associated with attention and behavioral control, fundamentally improving the core symptoms of hyperactivity.-Fineline Info & Tech